Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 14, 2006; 12(2): 204-213
Published online Jan 14, 2006. doi: 10.3748/wjg.v12.i2.204
Published online Jan 14, 2006. doi: 10.3748/wjg.v12.i2.204
Table 2 Combination therapy for advanced gastric cancer
| Response rat (%) | Median survival (mo) | |
| FU-based combinations | ||
| FAM | 30-42 | 6-9 |
| FAMTX | 33-63 | 6 |
| ELF | 53 | 11 |
| Modified-ELF | 16-42 | 6-9.5 |
| Cisplatin-5-FU CI synergism | ||
| PF | 40 | 9-10 |
| ECF | 59-71 | 8.7 |
| P-5-FU 48-h CI | 50 | 9.3 |
| P-5FU 24-h CI | 58 | 11 |
| Cisplatin-based combinations | ||
| EAP | 33-64 | 9 |
| FLEP | 35 | 8 |
| FLEP-type | 39 | 11 |
| LV5FU2-P | 27 | 13.3 |
| Combinations including new drugs | ||
| P-CPT11 | 41-58 | 9-12 |
| LOHP-CPT11 | 50 | 8.5 |
| CPT11-bolus 5-FU | 22 | 7.6 |
| CPT11- 5-FU CI | 20 | 7 |
| P-Xeloda | 54.8 | 10.1 |
| ECC | 59 | 9.6 |
| P-S-1 | 73-74 | 12 |
| TPFU/LV | 50 | 11-14 |
| DP | 37-56 | 9-11 |
| DPF | 51 | 9.3 |
- Citation: Sastre J, García-Saenz JA, Díaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol 2006; 12(2): 204-213
- URL: https://www.wjgnet.com/1007-9327/full/v12/i2/204.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i2.204